Congratulations to lab members, Anthony Kang, and colleagues for our manuscript newly accepted in Antimicrobial Agents and Chemotherapy titled: "​Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model"

The manuscripts describes potent in vitro and in vivo activity of the apramycin, an aminocyclitol aminoglycoside, against multidrug-resistant and extensively-drug resistant Acinetobacter baumannii.  

In prior manuscripts, we demonstrated broad activity against several types of multidrug-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter  baumannii and Pseudomonas aeruginosa

The laboratory has been fortunate to participate in Harvard Catalyst Reactor Program through the "Big Ideas, Small Features” Pilot Grant Award.  A description of the program was recently published last week in Harvard Medical School news titled "Catalyzing Research Innovation."    

A description of the supported work can be found at: "Reactor Program Awards Eight New Pilot Grants: Supports researchers with novel solutions to major clinical challenges."

Thea was awarded an Academy of Clinical Laboratory Physicians and Scientists (ACLPS) Paul E. Strandjord Young Investigator Research Grant to study antimicrobial synergy against multidrug-resistant pathogens! 

"These grants are for research relevant to clinical laboratory science, clinical pathology, and laboratory medicine. Proposed research may be clinical, translational, basic science, quality improvement, and/or regulatory.

As this grant program is designed for young investigators, grant recipients must either be in training (residency and/or clinical or research fellowship) OR less than three years after their first faculty appointment (any level) at the time of application" . (quoted from: ​http://www.aclps.org/grant.html)

In the past, there have been only three such awards given nationally in a given year.